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THE LANCET
No
retinopathy
(n=13)
Retinopathy
(n=l2)
Raised homocysteine* 3 (23-1%) 8 (66-7%Jt
Age (yr) 45-5 (4-6) 44*2 (5-4)
Sex (m/f) 9/4 9 /4
Systolic BP (mm Hg) 124 (14) 122 (16)
Diastolic BP (mm Hg) 77(7) 78(8)
Total cholesterol 6-3(1-1) 5-4 (1-3)
(mmol/L)
Smokerst 8 (66*7%) 5 (45-4%)
Creatinine (mmol/L) 79-6 (15-6) 81-3 (16-2)
BP=blood pressure. Values are mean (SD). * Plasma 
homocysteine 5=10 pmoi/L. tP<0*03. I^nformation on 
smoking is missing for two participants.
Clinical characteristics of participants 
and occurrence of moderate 
hyperhomocysteinaemia
been shown to be associated with the 
thermolabile phenotype.1 Neugebauer 
and colleagues (Feb 15, p 473)a report 
a significantly higher prevalence of the 
modified allele in diabetic patients with 
retinopathy, but did not assess whether 
this association is mediated by plasma 
concentrations of homocysteine. We 
report on the association between 
moderate hyperhomocysteinaemia and 
retinopathy in 25 consecutive patients 
with insulin-dependent diabetes (WHO 
criteria) aged 35-59 years who had had 
diabetes for at least 10 years.
We measured plasma concentrations 
of homocysteine by a previously 
described m ethod .3 Retinopathy was 
assessed by fundus photography 
according to the EURODIAB 
protocol;4 the observer was unaware of 
biochemical data. Significant 
differences between frequencies were 
tested by Fisher’s exact test. 12 patients 
had retinopathy and 13 did not. None 
of the patients had clinical or 
biochemical signs of kidney disease. 
M oderate hyperhomocysteinaemia— 
plasma concentration of homocysteine 
above 10 jimol/L, which corresponds to 
the 90th percentile of the distribution 
of a non-diabetic population of similar 
age—was significantly more common in 
patients who had retinopathy than in 
those who did not (p<0'03, table).This 
finding accords with that of 
Neugebauer and colleagues and 
suggests that moderate hyperhomo­
cysteinaemia is associated with diabetic 
retinopathy and represents a link 
between this condition and the 
mutation in the M T H F R  gene.
An increase in plasma homocysteine 
of the same magnitude as that seen in 
the patients with diabetic retinopathy is 
associated with increased 
cardiovascular risk in individuals who 
do not have diabetes.5 Hyperhomo­
cysteinaemia may accelerate cell injury 
and platelet-mediated intimal 
proliferation of smooth muscle cells 
which lead to enhanced atherogenesis. 
Cell injury at the level of the small 
vessels may also contribute to the 
development of diabetic retinopathy. In
patients with insulin-dependent 
diabetes3 the major cardiovascular risk 
factors do not explain the excess 
cardiovascular morbidity and mortality. 
Conversely, macroangiopathy at the 
level of the heart and legs is associated 
with clinical signs of microangiopathy, 
such as retinopathy and kidney disease. 
Thus, moderate hyperhomo­
cysteinaemia may represent a 
mechanism that accounts for the 
concomitant presence of the two 
conditions in patients with insulin- 
dependent diabetes.
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Hormone replacement 
therapy and high 
incidence of breast 
cancer between 
mammographie screens
S ir— Several research groups have 
found that the interval cancer rate— 
ie, the incidence of breast cancer in 
the interval between mammographie 
screens* is higher in the N H S Breast 
Screening Programme than had been 
expected from the findings of the 
Swedish two county trial of 
mammographie screening.1,2 Threlfall 
and colleagues (Feb 15, p 47 2)3 now 
report that the interval cancer rate is 
comparatively higher among women 
aged 50-59 than among those aged 
60-64 at screening. One factor that 
needs to be considered is that the use 
of hormone replacement therapy by 
women screened in the U K  may
contribute to this relatively high rate of 
interval cancer. Randomisation for the 
Swedish trial was done in 1977-80, 
when use o f  hormone replacem ent 
therapy was rare, whereas among the 
women in the N H S  Breast Screening 
Programme, the prevalence of use of 
ho rm one  replacem ent therapy  was 
about 15% in 1990 an d  30% in 
1995 (unpublished observations), and 
was twice as frequent among women 
aged 50-59 years than among those 
aged 60-64 years.4
Use of hormone rep lacem en t 
therapy at the time o f  screening 
increases the mammographic density 
of breast tissue. Laya and colleagues1 
study5— the only study of which we are 
aware that looked at interval cancers in 
relation to the use o f  ho rm one  
replacement therapy—suggests tha t its 
use lowers the chance o f  a woman 
having h e r  cancer de tec ted  at 
screening, thereby increasing the rate 
of interval cancer. They reported that 
com pared  with never-users of 
horm one replacem ent therapy, the 
relative risk of having an interval 
cancer diagnosed in the first year of 
mammography as opposed to a screen- 
detected cancer was 5*2 for current 
users of horm one replacement therapy 
and 1-1 for former users .5 However, 
these findings are based on only seven 
women with interval cancer and the 
study was conducted in  the USA 
where annual screening is common, so 
no data were presented for cancers 
diagnosed beyond the first year after 
screening. Nevertheless, if correct, and 
if the effect of hormone replacement 
therapy on interval cancers persists for 
2 years, these results indicate that 
among women screened in the U K  in 
1990, about 700 extra interval cancers 
would have been diagnosed among 
users of horm one replacement therapy. 
This excess is sufficient to account for 
the h igher than  expected ra te  of 
interval cancer in the N H S  Screening 
Programme as a whole, including the 
higher rate among women aged 50-59 
than  am ong those aged 60 -64 . 
Moreover, quite apart from its effect 
on mammography, any increase in the 
background incidence of breast cancer 
due to use of hormone replacement 
therapy would also increase the 
num ber of interval cancers diagnosed.
W ith  the  large an d  increasing 
num ber of women who are users of 
horm one replacement therapy, it is 
im portant to know the extent to which 
this therapy contributes to the high 
rate of interval cancer seen in the N H S 
Breast Screening P rogram m e. T he  
available evidence is too uncertain  to 
guide policy. However, if  current use 
but n o t  form er use, of h o rm o n e  
rep lacem ent therapy lowers the 
efficacy of screening, there might be a 
simple way to reduce the ra te  of
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interval cancer; for example, by- 
suggesting that women stop using 
hormone replacement therapy for a 
short period before being screened.
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Sir—Threlfall and colleagues1 show 
that the incidence of interval cancer is 
dependent on age* and suggest that the 
interval between m am m ographic  
screenings should depend on the age of 
the individual. We report data from the 
Limburg breast cancer screening 
programme* which began  in 
December, 1990, as p a r t  of the 
Netherlands Screening Program m e .2
Women aged 49-69 years are 
selected by the population register o f  
the municipalities and invited by letter 
to take p a r t  in the screening 
programme once every 2 years. At 
the initial examination two-view 
mammography is done. T he  
mammograms are evaluated 
independently by two radiologists. To 
assess the quality of the screening 
programme* these files (women 
screened until Decembers 1994) were 
linked with those from the Maastricht 
cancer registry (breast cancer cases 
diagnosed until December 1995). The 
expected number of cases of breast 
cancer was calculated from the age- 
specific incidence rates for the 
Netherlands cancer registry in 1989, 
after adjustment for the  lower
incidence in the catchment area of the
i
Maastricht cancer registry.3’4 Since 
December, 1990, 90 001 women have 
taken part in a first round of screening. 
Record linkage with the cancer registry 
showed that 147 cases of invasive 
breast cancer were diagnosed in the 23 
months after a negative screening result
interval since 
screening 
by age-group
Observed
cases
Expected
cases
Observed/
expected
rate
49 years 
(n=9006)
0-11 months 7 10-3 0*68
12-23 months 9 7-8 1-16
Total 16 18-0 0-89
50-54 years 
(n=26164)
0-11 months 21 40-2 0-52
12-23 months 22 34-3 0-64
Total 43 74-5 0-58
55-59 years 
(n-20 326)
0-11 months 11 38-5 0-29
12-23 months. 25 34-1' 0-73
Total 36 72-6 0-50
60-64 years 
(n=19 231)
0-11 months 11 40’3 0-27
12-23 months 19 35*7 0-53
Total 30 76-0 0-39
65-69 years 
(n=17 759)
0-11 months 5 36-8 0-14
12-23 months 17 33*8 0-50
Total 22 70*6 0*31
Number of women screened includes all women 
screened for the first time in the breast cancer 
screening programme.
Observed and expected number of cases 
of Interval breast cancer by age-group 
and interval since screening, Maastricht 
cancer registry, 1990-95
(328*3 cases would be expected 
without screening). Rates of interval 
cancer were highest am ong the 
youngest age groups: in the first year 
after m am m ography, the estimated 
rates of observed cases to expected 
cases was 0*68 in women aged 49 
years, compared with 0*14 in women 
aged 65-69 years (p<0*0015 table). In  
the second year after mammography^ 
this ratio was estimated to be 1-16 in 
women aged 49 years versus 0-50 in 
those aged 65-69 years (p=0-001).
Among women who take part in 
screening for breast cancer5 age is an 
important determinant of the risk of 
having a diagnosis of breast cancer 
made in the interval between two 
screening rounds. Options to reduce 
the rate of interval cancers include the 
development of new screening tools3 
such as digital m am m ography  or 
com puter-assisted screening for 
younger (premenopausal) women ,3 and 
the introduction of a programme in 
which the frequency of screening is 
dependant on the women’s age.
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A research culture that 
asks too much
S ir —As a practising clinician with an 
interest in forensic medicine I am all 
too aware that medicine in the U K  has 
all but been destroyed by a research 
culture that has demanded and been 
given far too much, both in resources 
and influence, as you point out in your 
Feb 22 editorial.1 The impossible has 
always been demanded of the academic 
clinician and it has always resulted in 
the same response, a neglect of teaching 
duties in favour of attendance at 
conferences or committees by senior 
researchers, whereas the more junior 
doctors to whom the task has been 
delegated remain in the research 
laboratory.
The emphasis on research is 
producing dangerously inept clinicians 
and surgeons. Spending large chunks of 
one’s early career focused on a tiny area 
of medicine inevitably reduces the time 
available for gaining the broad 
knowledge and experience necessary to 
the practising doctor. In 1974, as a 
newly qualified doctor, I was already 
shocked by the narrowness of the 
competence of newly appointed 
consultants. They seemed to be one- 
disease men, visibly floundering out of 
their depth when fairly common 
conditions outside their field 
inconveniently appeared in their 
patients. Now this failing is sadly 
reflected in my forensic experience: 
patients admitted to general hospitals 
with common conditions are not being 
diagnosed or adequately treated. 
Patients are being asked to pay too high 
a price for the development of their 
doctors’ critical faculty.
It is a myth that all doctors must 
spend time in academic research in 
order to become good clinicians and 
competent surgeons. In my experience: 
most young people go into medicine 
with the aim of treating patients. Only
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